id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2002-E-0120-0006,FDA,FDA-2002-E-0120,Letter from U.S. Patent and Trademark Office to GlaxoSmithKline,Rule,Certificate Extending Patent Term,2007-04-23T04:00:00Z,2007,4,,,2025-10-02T20:00:05Z,,0,0,0900006480490324
FDA-2002-E-0120-0005,FDA,FDA-2002-E-0120,Notice of Final Determination,Other,Letter(s),2007-02-06T05:00:00Z,2007,2,,,2025-10-02T19:57:57Z,,0,0,0900006480490323
FDA-2002-E-0120-0004,FDA,FDA-2002-E-0120,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2007-01-10T05:00:00Z,2007,1,,,2025-10-02T19:54:42Z,,0,0,0900006480490322
FDA-2002-E-0120-0003,FDA,FDA-2002-E-0120,Determination of Regulatory Review Period for Purposes of Patent Extension; DUTASTERIDE,Notice,General Notice,2006-06-14T04:00:00Z,2006,6,2006-06-14T04:00:00Z,,2025-10-02T19:51:44Z,E6-9224,0,0,0900006480490321
FDA-2002-E-0120-0002,FDA,FDA-2002-E-0120,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2006-05-25T04:00:00Z,2006,5,,,2025-10-02T19:33:29Z,,0,0,0900006480490320
FDA-2002-E-0120-0001,FDA,FDA-2002-E-0120,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2006-05-25T04:00:00Z,2006,5,,,2025-10-02T19:31:09Z,,0,0,09000064804902d6